410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients.

AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)

AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart.

Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs.

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. IPO in June 2021 (NASDAQ: CVRX).

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke.

SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency.

Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
